Aviso Wealth Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
General Mills
GIS
|
+$1.01M |
| 2 |
Pfizer
PFE
|
+$947K |
| 3 |
Starbucks
SBUX
|
+$854K |
| 4 |
Consolidated Edison
ED
|
+$671K |
| 5 |
Bristol-Myers Squibb
BMY
|
+$639K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Strategy Inc
MSTR
|
+$1.44M |
| 2 |
Diamondback Energy
FANG
|
+$725K |
| 3 |
PG&E
PCG
|
+$696K |
| 4 |
Biogen
BIIB
|
+$369K |
| 5 |
Nasdaq
NDAQ
|
+$369K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 29.03% |
| 2 | Communication Services | 14.36% |
| 3 | Financials | 12.84% |
| 4 | Consumer Discretionary | 9.24% |
| 5 | Healthcare | 9.19% |
Similar funds
Aviso Wealth Management's Q1 2024 Portfolio in Review
As of Q1 2024, Aviso Wealth Management held 161 positions worth $159M, up 15% from $138M the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Aviso Wealth Management deployed $6.44M of net new capital in Q1 2024, opening 14 new positions and adding to 84 existing holdings. Its largest new stake was Union Pacific: 1,280 shares worth $315K.
By sector, the portfolio is most concentrated in Technology at 29% of assets, down from 29% a quarter earlier, followed by Communication Services and Financials.
On the sell side, the largest reduction was Strategy Inc, an estimated $1.44M trimmed.
- Aviso Wealth Management's largest Q1 2024 buy was Union Pacific: 1,280 shares worth $315K.
- Aviso Wealth Management added most to General Mills in Q1 2024, an estimated $1.01M increase.
- Aviso Wealth Management's biggest Q1 2024 reduction was Strategy Inc, cutting an estimated $1.44M.
- Aviso Wealth Management fully exited Biogen in Q1 2024, selling an estimated $369K.
- Aviso Wealth Management's ten largest holdings make up 39% of its $159M portfolio in Q1 2024.
- Aviso Wealth Management opened 14 new positions and closed 13 in Q1 2024.
- Aviso Wealth Management's portfolio value rose 15% quarter-over-quarter to $159M.
Based on Aviso Wealth Management's 13F filing for Q1 2024, filed 14 May 2024.